Day: May 9, 2022

Conference Call Today at 10 a.m. ET PARSIPPANY, N.J., May 09, 2022 (GLOBE NEWSWIRE) — Lincoln Educational Services Corporation (Nasdaq: LINC) today, reported operating and financial results for the first quarter as well as recent business developments. First Quarter 2022 vs First Quarter 2021 Financial Highlights and Recent Operating DevelopmentsRevenue of $82.6 million, up 5.8% compared to prior year Adjusted EBITDA* of $2.4 million, compared to $5.4 million in prior year Average student population up 4.4% Beginning period population up 6.0% Reiterating 2022 guidance for all metrics including student starts, revenue, Adjusted EBITDA, net income and capital expenditures*See Use of “Non-GAAP Financial Information” below. “Our first quarter performance reflects the strong demand for Lincoln’s programs despite an exceptionally...

Atlantica Reports First Quarter 2022 Financial ResultsRevenue for the first three months of 2022 reached $247.5 million, a 7.0% increase year-over-year on a comparable basis1 and a 7.7% decrease year-over-year. Adjusted EBITDA was $173.6 million for the first three months of 2022, a 4.8% increase year-over-year on a comparable basis1 and a 1.4% year-over-year increase. Net loss for the first quarter of 2022 attributable to the Company was $12.0 million, compared with a net loss of $19.2 million in the first quarter of 2021. Cash available for distribution (“CAFD”) increased by 6.3% year-over-year up to $54.4 million in the first quarter of 2022. Quarterly dividend of $0.44 per share approved by the Board of Directors. $140 – 150 million in equity investments already closed or earmarked for 2022.May 9, 2022 – Atlantica Sustainable...

CUPERTINO, CA, May 09, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Aemetis, Inc. (NASDAQ: AMTX) announced that the company will host a conference call to review the release of its first quarter 2022 earnings report: Date: Thursday, May 12, 2022 Time: 11 am Pacific Standard Time (PST) Live Participant Dial In (Toll Free): +1-888-506-0062 entry code 841388 Live Participant Dial In (International): +1-973-528-0011 entry code 841388 Webcast URL: https://www.webcaster4.com/Webcast/Page/2211/45517 Attendees may submit questions during the Q&A portion of the conference call.  The webcast will be available on the Company’s website (www.aemetis.com) under Investors/Conference Calls, along with the company presentation, recent announcements and  video recordings. The voice recording will be available through May 19, 2022 by dialing (Toll...

Consolidated Net Revenue of $11.9 Million Up 6% vs. First Quarter of 2021 U.S. Net Revenue Increased 23% vs. First Quarter of 2021 U.S. End User Demand Up 25% vs. First Quarter of 2021ATLANTA, May 09, 2022 (GLOBE NEWSWIRE) — Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the first quarter of 2022. Alimera will host a conference call on May 9th, 2022, at 9:00 a.m. ET to discuss these results and provide an update on corporate developments. “We are pleased with the continuing trend that we see in the U.S. market as we report another consecutive quarter of end user demand growth over the prior year period,” said Rick Eiswirth,...

$221.4 million in cash and short-term investments VANCOUVER, British Columbia, May 09, 2022 (GLOBE NEWSWIRE) — Sabina Gold & Silver Corp. (“Sabina”) or (the “Company”) (SBB – TSX/ SGSVF – OTCQX) reports the interim financial results for the quarter ended March 31, 2022. “The first quarter culminated one of the most important milestones for the Company to date as we advance towards gold production,” said Bruce McLeod, the Company’s President & CEO. “Not only did we complete debt and streaming agreements on acceptable terms, but we also raised the equity component of our construction financing package. We believe Sabina truly stands apart among its peers as one of the only fully permitted, social licensed, engineered and financed projects in a tier one jurisdiction. We acknowledge our tremendous support in Nunavut...

Cash, cash equivalents, restricted cash and marketable securities of $36.6 million as of March 31, 2022 Additional data from RESCUE-ALS presented at 2022 AAN Annual Meeting and MDA Clinical & Scientific Conference; Results show significant survival benefit in participants who entered open-label extension study Top-line results from studies in ALS, MS and COVID-19 programs expected in third quarterSALT LAKE CITY, May 09, 2022 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today reported its first quarter 2022 and recent operating highlights. “As we approach the second half of 2022, we expect to report data readouts for...

The FDA cleared the investigational new drug application for CTX-009 (DLL4 X VEGF-A bispecific) in January allowing the Company to expand the ongoing Phase 2 study in patients with biliary tract cancer (BTC) to a global study and initiate dosing patients in the United States in early Q3 of 2022 The Company reported interim data from the ongoing Phase 2 study of CTX-009 and paclitaxel in patients with advanced BTC demonstrating a 42% overall response rate (ORR) and 92% clinical benefit rate (CBR) among the first 24 patients enrolled and dosed with interim median patient time on study of ~ 6 monthsThe Company completed enrollment in the CTX-471 (CD137 agonist) Phase 1b monotherapy study and reported 3 partial responses in patients with advanced solid tumors who were dosed with CTX-471 following progression on a prior PD-1/PD-L1 checkpoint...